{"id":"norelgestromin-ethinyl-estradiol","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-15","effect":"Breakthrough bleeding"},{"rate":"2-5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"},{"rate":"2-5","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL3544698","moleculeType":"Small molecule","molecularWeight":"312.41"},"_dailymed":{"setId":"fbbd12dd-c538-2869-e053-6294a90a1a38","title":"ZAFEMY (NORELGESTROMIN AND ETHINYL ESTRADIOL) PATCH [AVKARE]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Norelgestromin is a progestin that provides contraceptive efficacy primarily through cervical mucus thickening and endometrial atrophy, while ethinyl estradiol is an estrogen that enhances ovulation suppression and stabilizes the endometrium. Together, they prevent the LH surge necessary for ovulation and create an unfavorable environment for sperm transport and implantation.","oneSentence":"Norelgestromin and ethinyl estradiol work together as a hormonal contraceptive by suppressing ovulation through inhibition of gonadotropin-releasing hormone (GnRH) and feedback inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:36.394Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception (prevention of pregnancy)"},{"name":"Regulation of menstrual cycle"}]},"trialDetails":[{"nctId":"NCT07083635","phase":"PHASE2","title":"Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users","status":"RECRUITING","sponsor":"Chulalongkorn University","startDate":"2025-07-29","conditions":"Menstruation Disturbances, Metrorrhagia, Uterine Hemorrhage","enrollment":40},{"nctId":"NCT05139121","phase":"PHASE3","title":"Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles","status":"COMPLETED","sponsor":"Mylan Technologies Inc.","startDate":"2021-10-26","conditions":"Contraception","enrollment":1319},{"nctId":"NCT04423068","phase":"EARLY_PHASE1","title":"Inpatient Adolescent Contraception","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2020-12-10","conditions":"Pregnancy Related, Contraception, Contraceptive Usage","enrollment":25},{"nctId":"NCT01044056","phase":"PHASE4","title":"A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Contraception","enrollment":24},{"nctId":"NCT02367833","phase":"PHASE4","title":"Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis","status":"COMPLETED","sponsor":"Penn State University","startDate":"2015-01","conditions":"Bone; Disorder, Development and Growth","enrollment":60},{"nctId":"NCT00377988","phase":"","title":"A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-04","conditions":"Contraception, Female Contraception","enrollment":423},{"nctId":"NCT00331071","phase":"","title":"Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-04","conditions":"Contraception, Female Contraception","enrollment":334},{"nctId":"NCT00511784","phase":"","title":"Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Contraception, Female Contraception, Fertility Control","enrollment":440},{"nctId":"NCT00185354","phase":"PHASE3","title":"FC Patch Comparator Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-11","conditions":"Contraception","enrollment":422},{"nctId":"NCT01458210","phase":"PHASE1","title":"A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":22},{"nctId":"NCT02127593","phase":"PHASE1","title":"A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-06","conditions":"Healthy","enrollment":101},{"nctId":"NCT00984789","phase":"PHASE3","title":"Birth Control Patch Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-05","conditions":"Contraception","enrollment":393},{"nctId":"NCT01535820","phase":"PHASE1","title":"The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-03","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT01087879","phase":"NA","title":"The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2007-10","conditions":"Contraception","enrollment":45},{"nctId":"NCT00320580","phase":"PHASE2","title":"An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen","status":"COMPLETED","sponsor":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","startDate":"","conditions":"Metrorrhagia","enrollment":239},{"nctId":"NCT00775086","phase":"PHASE1","title":"Bioequivalence Study of Patches With Different Equilibration Profiles","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-05","conditions":"Female Contraception","enrollment":42},{"nctId":"NCT00236795","phase":"PHASE3","title":"A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-01","conditions":"Contraception, Female Contraception","enrollment":1494},{"nctId":"NCT00236782","phase":"PHASE3","title":"A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-10","conditions":"Contraception","enrollment":1517},{"nctId":"NCT00258063","phase":"PHASE1","title":"A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-05","conditions":"Contraception, Female Contraception","enrollment":60},{"nctId":"NCT00697307","phase":"","title":"Bioequivalence Study of Patches With Different Release Profiles","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-03","conditions":"Female Contraception","enrollment":43},{"nctId":"NCT00254865","phase":"PHASE1","title":"A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-08","conditions":"Contraception, Female Contraception","enrollment":34},{"nctId":"NCT00439972","phase":"PHASE2","title":"Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity","status":"UNKNOWN","sponsor":"University of Washington","startDate":"2007-02","conditions":"Contraception","enrollment":36},{"nctId":"NCT00236769","phase":"PHASE3","title":"A Study of Efficacy and Safety With the Transdermal Contraceptive System.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-11","conditions":"Contraception, Female Contraception","enrollment":1751},{"nctId":"NCT00261482","phase":"PHASE4","title":"Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2003-07","conditions":"Contraception, Female Contraception","enrollment":778},{"nctId":"NCT00653016","phase":"PHASE4","title":"An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2002-10","conditions":"Female Contraception","enrollment":405},{"nctId":"NCT00269620","phase":"PHASE4","title":"PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2005-06","conditions":"Contraception","enrollment":500},{"nctId":"NCT00554632","phase":"NA","title":"Birth Control Pill vs Birth Control Patch Study","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2003-04","conditions":"Venous Thrombosis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"norelgestromin + ethinyl estradiol","genericName":"norelgestromin + ethinyl estradiol","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Norelgestromin and ethinyl estradiol are a small molecule combination used for female contraception. They are also being studied in relation to their effect on how the body handles oral contraceptives in healthy female participants with type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}